# Itepekimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/itepekimab

> Itepekimab, sponsored by Sanofi (SNY): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | itepekimab |
| Codes | SAR440340 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | copd in two phase 3 studies aerify-1 |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### 2H 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: COPD in two phase 3 studies AERIFY-1.
- First seen 2025-04-16, last confirmed 2025-04-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-082251): "Itepekimab is currently being explored in patients with COPD in two phase 3 studies AERIFY-1 (clinical study identifier: NCT04701983) and AERIFY-2 (clinical study identifier: NCT04751487) with the readout anticipated in H2 2025, and in one phase 2 study, AERIFY-3 (clinical study identifier: NCT05326412), with the readout anticipated in H2 2025." https://www.sec.gov/Archives/edgar/data/1121404/000119312525082251/d941050dex991.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-04-16, last confirmed 2025-04-16.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-082251): "Finally, itepekimab is being explored in a phase 2 study (clinical study identifier: NCT06280391) in bronchiectasis, with the readout anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1121404/000119312525082251/d941050dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/itepekimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Itepekimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/itepekimab

```bibtex
@misc{secapidev_pdufa_itepekimab_20261116,
  title        = {Itepekimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/itepekimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_itepekimab_20261116","title":"Itepekimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/itepekimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
